Eisai Co. Ltd. has announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, to co-develop and co-commercialize the cancer treatment lenvatinib. This partnership will see the two companies working together on both monotherapy applications and combinations with Merck's anti-PD-1 therapy, pembrolizumab. The collaboration includes a focus on the LEAP clinical program, which explores the combination of lenvatinib and pembrolizumab in treating hepatocellular carcinoma and esophageal cancer across various clinical trials. This initiative highlights Eisai and Merck's commitment to advancing oncology treatment options and improving patient outcomes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。